{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:29Z","timestamp":1793298929828,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.05.013","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T19:59:02Z","timestamp":1779825542000},"page":"874-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radioligand Therapy (RLT) in France"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-1254","authenticated-orcid":false,"given":"Anne-Laure","family":"Giraudet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kryza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Vija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Cachin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Sala\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Courbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.05.013_b0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mednuc.2024.09.001","article-title":"\u00c9tude capacit\u00e9 th\u00e9ranostique 2023\u20132024 \u2013 mod\u00e9lisation sur la base de la RIV-PSMA. Radioth\u00e9rapie interne vectoris\u00e9e (RIV), une approche th\u00e9ranostique \u00e0 laquelle le patient doit avoir acc\u00e8s. Partie I: consolidation nationale","volume":"48","author":"Giraudet","year":"2024","journal-title":"Med Nucl\u00e9aire"},{"key":"10.1016\/j.euf.2026.05.013_b0010","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","article-title":"Strategies of radioiodine ablation in patients with low-risk thyroid cancer","volume":"366","author":"Schlumberger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.05.013_b0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa2111953","article-title":"Thyroidectomy without radioiodine in patients with low-risk thyroid cancer","volume":"386","author":"Leboulleux","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.05.013_b0020","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2023.0240","article-title":"MERAIODE: a phase II redifferentiation trial with trametinib and 131 I in metastatic radioactive iodine refractory RAS mutated differentiated thyroid cancer","author":"Leboulleux","year":"2023","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.euf.2026.05.013_b0025","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2967\/jnumed.123.267363","article-title":"Peptide receptor radionuclide therapy or everolimus in metastatic neuroendocrine tumors: the SeqEveRIV study, a national study from the French group of endocrine tumors and endocan-RENATEN network","volume":"65","author":"Fosse","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.013_b0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2967\/jnumed.123.266063","article-title":"Outcome on mesenteric mass response of small-intestinal neuroendocrine tumors treated by 177Lu-DOTATATE peptide receptor radionuclide therapy: the MesenLuth study, a national study from the French group of endocrine tumors and endocan-RENATEN network","volume":"65","author":"Al Mansour","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.05.013_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.mednuc.2026.02.001","article-title":"Radioth\u00e9rapie interne vectoris\u00e9e et th\u00e9ranostique en France: recommandations de bonnes pratiques par la Soci\u00e9t\u00e9 Fran\u00e7aise de M\u00e9decine Nucl\u00e9aire","author":"Bailly","year":"2026","journal-title":"Med Nucl\u00e9aire"},{"key":"10.1016\/j.euf.2026.05.013_b0040","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.05.013_b0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.mednuc.2024.12.015","article-title":"Analyse descriptive de la plus grande cohorte mondiale de patients atteints de CPRCm trait\u00e9s en acc\u00e8s pr\u00e9coce par [177Lu]Lu-PSMA-617","volume":"49","author":"Girault","year":"2025","journal-title":"Med Nucl\u00e9aire"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:58:25Z","timestamp":1793296705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405456926000817"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.013","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioligand Therapy (RLT) in France","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}